S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Furiex Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:FURX)

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
Current SymbolNASDAQ:FURX
CUSIP36106P10
WebN/A
Phone+1-919-4567800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive FURX News and Ratings via Email

Sign-up to receive the latest news and ratings for FURX and its competitors with MarketBeat's FREE daily newsletter.


Furiex Pharmaceuticals (NASDAQ:FURX) Frequently Asked Questions

What is Furiex Pharmaceuticals' stock symbol?

Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."

Has Furiex Pharmaceuticals been receiving favorable news coverage?

Headlines about FURX stock have trended very negative on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Furiex Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Furiex Pharmaceuticals.

Who are some of Furiex Pharmaceuticals' key competitors?

What other stocks do shareholders of Furiex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Furiex Pharmaceuticals investors own include Pretium Resources (PVG), Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Baidu (BIDU), Cisco Systems (CSCO), Gilead Sciences (GILD), Alphabet (GOOG), Incyte (INCY), Intuitive Surgical (ISRG) and Medivation (MDVN).

How do I buy shares of Furiex Pharmaceuticals?

Shares of FURX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How can I contact Furiex Pharmaceuticals?

Furiex Pharmaceuticals' mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800.


MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe FURX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FURX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel